Biotech companies at Cell 2026

Nov 12–13, 2026 London, UK ~800 attendees Website

28 biotech companies are at Cell 2026 — 58 presentations on the program. Most represented: Resolution Therapeutics (4 on the program), TreeFrog Therapeutics (2 on the program), Autolus (2 on the program). 20 of them have their own page in this guide. As of Oct 8, 2026.

All 109 organizations at Cell 2026 →

Showing 1–12 of 28 organizations

Organization	Cell 2026 Attendance
Resolution Therapeutics London, UK
resolution-tx.com Biotech Develops regenerative macrophage therapies for inflammatory and fibrotic diseases, led by a programme in end-stage liver disease.	Talk Thu Nov 12 10:15am–10:40am Building For The Future: Phase-Appropriate CMC Strategies Manufacturing and CMC Panel Thu Nov 12 2:40pm–3:05pm The AI Reality Check: What’s Ready Now, What Isn’t, And How Do We Validate It Safely? with Hogan Lovells, TreeFrog Therapeutics Digital biomanufacturing and AI Panel Fri Nov 13 4:40pm–5:05pm Beyond Silos: How Cell & Gene Therapies Fit Into The Broader Biotech & Treatment Landscape with Cell and Gene Therapy Catapult, Leucid Bio Cell and gene therapy Panel Fri Nov 13 4:40pm–5:05pm Navigating The Regulatory Lifecycle Of Advanced Therapies: From Platform Approval To Manufacturing & Post-Market Evidence with Aspen Neuroscience, NHS Blood and Transplant Cell and gene therapyManufacturing and CMC Talk Fri Nov 13 5:05pm–5:30pm Developing A Regenerative Macrophage Therapy (RMT) For Fibro-Inflammatory Diseases: Challenges And Opportunities Cell and gene therapy
TreeFrog Therapeutics Bordeaux, France
treefrog.fr Biotech Develops cell therapies from pluripotent stem cells grown in its C-Stem 3D encapsulation platform, with a lead program in Parkinson's disease.	Panel Thu Nov 12 2:40pm–3:05pm The AI Reality Check: What’s Ready Now, What Isn’t, And How Do We Validate It Safely? with Hogan Lovells, Resolution Therapeutics Digital biomanufacturing and AI Panel Fri Nov 13 9:25am–9:50am Plenary Thought Leadership Panel Discussion: Turning Scientific Breakthroughs Into Sustainable Therapies – Building A Viable Business Model For CGTs with Orchard Therapeutics Cell and gene therapy Talk Fri Nov 13 11:40am–12:05pm Bridging Development and Manufacturing Through Predictive Scaling Manufacturing and CMCCell culture and upstream processing Talk Fri Nov 13 2:45pm–3:10pm Cell Therapy: From Therapeutic Potential To Sustainable Patient Access Cell and gene therapy
Autolus London, UK
autolus.com Biotech Develops and markets CAR-T cell therapies, including an approved treatment for adult acute lymphoblastic leukaemia.	Talk Thu Nov 12 3:05pm–3:30pm Harnessing Digital PCR For Rapid Sterility Testing Analytics and characterization Panel Thu Nov 12 5:20pm–5:45pm Overcoming Sterility Testing Challenges In CGT Analytical Development Analytics and characterizationCell and gene therapy Talk Fri Nov 13 5:05pm–5:30pm Developing Cutting-Edge Flow-Based Assays For Critical CMC Applications Analytics and characterizationManufacturing and CMC
AviadoBio London, UK
aviadobio.com Biotech King's College London spin-out developing gene therapies for neurodegenerative diseases such as frontotemporal dementia.	Panel Thu Nov 12 12:25pm–12:50pm Cracking In Vivo Delivery For Next-Generation Gene Therapies with University Medical Center Freiburg, SymphoRNA, AstraZeneca Cell and gene therapy Talk Thu Nov 12 2:40pm–3:05pm Manufacture Of AVB-406, A BBB-Crossing AAV Vector For MAPT Knockdown In Alzheimer's Disease Cell and gene therapyManufacturing and CMC Talk Thu Nov 12 5:45pm–6:10pm Leveraging Platform-Based RNA Silencing To Accelerate Rare Disease Therapeutic Development Cell and gene therapy
INmune Bio Boca Raton, Florida
inmunebio.com Biotech Clinical-stage company developing immune-targeted therapies, including a TNF inhibitor for neurological disease and an umbilical cord MSC therapy.	Talk Thu Nov 12 9:25am–9:50am Designing Large Scale Cell Therapies For Real-World Access Cell and gene therapyManufacturing and CMC Panel Fri Nov 13 1:55pm–2:20pm Closing The Gap: Connecting Upstream And Downstream Bioprocessing In Cell-Based Therapies with Quell Therapeutics, Technical University of Denmark Cell culture and upstream processingCell and gene therapy Talk Fri Nov 13 4:40pm–5:05pm MSC Therapies: From Decades Of Challenges To Commercial Approval Cell and gene therapyStem cells, organoids and cell models
Quell Therapeutics London, UK
quell-tx.com Biotech Develops engineered regulatory T-cell therapies for immune-mediated diseases and transplant rejection.	Panel Thu Nov 12 2:40pm–3:05pm Quality Control Strategies In Advanced CGTs with Bristol Myers Squibb, University of Liverpool Cell and gene therapyAnalytics and characterization Talk Thu Nov 12 5:20pm–5:45pm Lessons Learned From Cross-Team & Multi-Site Collaboration To Improve Assay Transfer & Scalability Analytics and characterization Panel Fri Nov 13 1:55pm–2:20pm Closing The Gap: Connecting Upstream And Downstream Bioprocessing In Cell-Based Therapies with Technical University of Denmark, INmune Bio Cell culture and upstream processingCell and gene therapy
Rinri Therapeutics Sheffield, UK
rinri-therapeutics.com Biotech Clinical-stage company developing regenerative cell therapies for sensorineural hearing loss.	Talk Thu Nov 12 4:55pm–5:20pm Featured Session: Restoring Hearing With Cell & Gene Therapies: From Bench To Bedside - Developing A World-First Regenerative Cell Therapy For Hearing Loss Cell and gene therapy Panel Thu Nov 12 5:45pm–6:10pm Featured Session: Restoring Hearing With Cell & Gene Therapies: From Bench To Bedside with University of Cambridge, Sensorion Cell and gene therapy Panel Fri Nov 13 11:40am–12:05pm From Model To Medicine: Fixing The Translation Gap with ValiRx, a:head bio, MeiraGTx Stem cells, organoids and cell models
ValiRx
valirx.com Biotech UK-listed oncology drug developer that evaluates and develops early assets; its Inaphaea BioLabs unit supplies patient-derived cancer cell models.	Panel Fri Nov 13 11:40am–12:05pm From Model To Medicine: Fixing The Translation Gap with Rinri Therapeutics, a:head bio, MeiraGTx Stem cells, organoids and cell models Talk Fri Nov 13 1:55pm–2:20pm Patient Derived Cells As New Approach Methodologies For More Predictive Oncology Models Stem cells, organoids and cell models
a:head bio Vienna, Austria
aheadbio.com Biotech Uses human brain organoid models to support neuroscience drug discovery.	Panel Fri Nov 13 11:40am–12:05pm From Model To Medicine: Fixing The Translation Gap with ValiRx, Rinri Therapeutics, MeiraGTx Stem cells, organoids and cell models Talk Fri Nov 13 2:45pm–3:10pm Human Brain Organoids In Drug Discovery Stem cells, organoids and cell models
A AeirBio
Biotech Memorial Sloan Kettering spin-out developing solid tumour therapies that act on the ceramide and ENT1 pathway to raise chemotherapy uptake.	Talk Fri Nov 13 12:05pm–12:30pm TTMEMs: Modifying Solid-Tumor Cell-Membrane Lipid Composition To Enhance Uptake Of Chemotherapeutic Agents Panel Fri Nov 13 2:45pm–3:10pm From Discovery To Deliverability: Building The Next Generation Of Cell & Gene Therapies with NKILT Therapeutics Cell and gene therapy
Axovia Therapeutics London, UK
axoviatherapeutics.com Biotech Develops gene therapies for genetic forms of obesity and ciliopathies, including Bardet-Biedl syndrome.	Talk Thu Nov 12 10:15am–10:40am The Development Of The AXIS Trial. Gene Therapy To Halt The Retinal Degeneration In Bardet-Biedl Syndrome Cell and gene therapy Panel Thu Nov 12 3:05pm–3:30pm Where Advanced Therapies Will Be In 2030: Scientific, Clinical, Regulatory & Economic Futures with NextCell Pharma, BioNTech Cell and gene therapy
BioNTech Mainz, Germany
biontech.com Biotech Develops mRNA vaccines and immunotherapies, including cell therapies and antibodies, mainly for cancer and infectious disease.	Panel Thu Nov 12 3:05pm–3:30pm Where Advanced Therapies Will Be In 2030: Scientific, Clinical, Regulatory & Economic Futures with NextCell Pharma, Axovia Therapeutics Cell and gene therapy Talk Fri Nov 13 4:15pm–4:40pm Emerging Regulatory Guidelines For Individualised Gene Therapies Cell and gene therapy